DoD’s $41M Wafermine Contract Is Separate From iX Biopharma’s Pending Manufacturing JV
The U.S. Department of Defense awarded iX Biopharma a $41 million contract in February 2026 to develop Wafermine, a ketamine-based treatment intended for military use. The company says the award is independent of its proposed joint venture with Orion Specialty Labs, while reimbursement timing, clinical trials and a revised emergency-use submission schedule create delivery and financing considerations.